Patents by Inventor Dange Veerapaneni

Dange Veerapaneni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prepartaion for external percutaneous administration containing non-steroidal anti-inflammatory drug and interleukin-1 alpha production inhibitor
    Publication number: 20060188557
    Abstract: A transdermal formulation for external application comprising a non-steroidal anti-inflammatory analgesic, an alkyl ester of gallic acid, and a phenolic radical scavenger having a branched-chain lower alkyl group. An interleukin-1? production inhibitor consisting of a phenolic radical scavenger having a branched-chain lower alkyl group, and/or an alkyl ester of gallic acid.
    Type: Application
    Filed: May 24, 2004
    Publication date: August 24, 2006
    Applicant: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Atsutoshi Ikesue, Kazuhisa Yoshitake, Kenji Atarashi, Koichi Ikesue, Michinori Sakai, Amarender Reddy, Yoshiteru Motoki, Dange Veerapaneni
  • Methods and compositions for inhibition of irritation by disaccharide and metal ions
    Publication number: 20030229048
    Abstract: Compositions for reducing an adverse skin reaction caused by a skin-irritating agent or skin sensitizing agent by treatment with a disaccharide and a metal ion, as well as methods for reducing an adverse skin reaction caused by a skin-irritating or skin-sensitizing agent, and methods for treating an inflammatory response to at least one inflammatory agent, by application of a disaccharide and/or metal ion composition.
    Type: Application
    Filed: April 30, 2003
    Publication date: December 11, 2003
    Inventors: Dange Veerapaneni, Kazutaka Inoue, Takaaki Yoshinaga, Munehiko Hirano, Shuji Sato
  • Ribozymes targeted to human IL-15 mRNA
    Patent number: 6087172
    Abstract: Enzymatic RNA molecules which cleave mRNA encoding IL-15, are provided. The constructs of the invention include regulatory regions for expression in cells, cell lines, or transgenic non-human animals. The ribozymes of the invention are directed against IL-15 mRNA and are useful in treating rheumatoid arthritis.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 11, 2000
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Dange Veerapaneni, Shoji Hamanaka, Iwao Nozawa